NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

• Conditions: Non-small Cell Lung Cancer

• Registration Number: NCT03764917
• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Brief Summary

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Detailed Description

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Study Timeline

• Study Start: 2018-12-01
• Study First Submitted: 2018-12-03
• Study First Submitted QC: 2018-12-03
• Study First Posted: 2018-12-05
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-22
• Last Update Posted: 2020-03-24
• Primary Completion: 2020-12-31
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy

Exclusion Criteria

EGFR mutant positive Alk mutant positive

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
numbers of immune cells	24 months	detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Secondary Outcome Measures

Name	Time	Method
numbers of tumor mutations	24 months	detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Trial Locations

Locations (1)

Shanghai Pulmonary Hospital; 🇨🇳 Shanghai, Shanghai, China